Keji Pharmaceutical-B (02171) issued an announcement. The company's board of directors announced that CT041 (a type of target Claud...
Zhitong Finance App News, Keji Pharmaceutical-B (02171) issued an announcement. The company's board of directors announced that the abstract of CT041 (a candidate product targeting Claudin18.2 autologous CAR-T cells) has been received for an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
According to reports, CT041 is a potential first-of-its-kind autologous CAR-T cell candidate product targeting Claudin18.2 protein. It is used to treat Claudin18.2 positive solid tumors, mainly gastric cancer/esophagogastric junction adenocarcinoma and pancreatic cancer. Ongoing trials include clinical trials initiated by researchers in China (CT041-CG4006, NCT03874897), confirmatory phase II clinical trials (CT041-ST-01, NCT04581473) for advanced gastric cancer/esophagastric junction adenocarcinoma, phase I clinical trials for adjuvant treatment of pancreatic cancer in China (CT041-ST-05, NCT05911217), and phase 1b/2 clinical trials for advanced gastric cancer or pancreatic cancer in North America ( CT041-ST-02, NCT04404595). In January 2022, CT041 was granted “Advanced Regenerative Medicine Therapy” (RMAT) certification by the US FDA to treat advanced gastric cancer/esophagastric junction adenocarcinoma positive for Claudin 18.2. In November 2021, CT041 was granted priority drug (PRIME) status by the European Medicines Agency (EMA) to treat advanced gastric cancer. In 2020 and 2021, CT041 was granted “orphan drug” certification by the US FDA for the treatment of gastric cancer/esophagastric junction adenocarcinoma and the EMA certified “orphan drug” for the treatment of advanced gastric cancer.
According to the announcement, the group is a biopharmaceutical company with operations in China and the US, focusing mainly on innovative CAR-T cell therapy for the treatment of hematologic malignancies and solid tumors. The company has established a CAR-T cell research and development platform from target discovery, innovative CAR-T cell development, clinical trials to commercial-scale production. Through independent research and development of new technologies and a product pipeline with global rights, the Group solves the major challenges of CAR-T cell therapy, such as improving safety, improving the efficacy of treating solid tumors, and reducing treatment costs. The company's mission is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients around the world and makes cancer curable.